(Q42363154)

28 October 2017

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. (English)

1 reference

28 October 2017

7

Carl H June

1 reference

28 October 2017

6

Bruce L Levine

1 reference

28 October 2017

3

Simon F Lacey

1 reference

28 October 2017

Elise A Chong

1

1 reference

28 October 2017

J Joseph Melenhorst

2

1 reference

28 October 2017

David E Ambrose

4

1 reference

28 October 2017

Vanessa Gonzalez

5

1 reference

28 October 2017

Stephen J Schuster

8

1 reference

28 October 2017

language of work or name

English

0 references

publication date

28 December 2016

1 reference

28 October 2017

1 reference

28 October 2017

129

1 reference

28 October 2017

8

1 reference

28 October 2017

1039-1041

1 reference

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

28 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Nivolumab plus ipilimumab in advanced melanoma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391777

10.1182/BLOOD-2016-09-738245

17 August 2018

Identifiers

DOI

1 reference

28 October 2017

1 reference

28 October 2017

1 reference